Dr. Morgan received her Ph.D. in Genetics and Developmental Biology in 2002 from West Virginia University. She completed her post-doctoral training in Radiation Biology under the mentorship of Dr. Ted Lawrence at the University of Michigan during which she developed CHK1 inhibitors as chemoradiation sensitizers. In 2009, Dr. Morgan was appointed Assistant Professor of Radiation Oncology at the University of Michigan and continued her research efforts in the fields of the DNA damage response and experimental therapeutic radiation sensitizers. In 2014, Dr.
Mohammad Fallahi-Sichani obtained his bachelor’s degree in Biotechnology from the University of Tehran in 2007. In 2012, he earned a Ph.D. in Chemical Engineering from the University of Michigan, where he was awarded a Rackham Predoctoral Fellowship and a Richard and Eleanor Towner Prize for Outstanding PhD Research. His PhD work co-mentored by Dr. Jennifer Linderman and Dr. Denise Kirschner combined multi-scale modeling approaches with wet-lab experiments to the study of mechanisms by which TNF signaling determines immunity to M. tuberculosis infection.
Dr. Keller obtained Doctor of Veterinary Medicine (D.V.M.) and Masters of Preventive Veterinary Medicine (M.P.V.M.) degrees from the University of California, Davis and a doctorate (Ph.D.) in Developmental Biology from the University of Wisconsin, Madison. Currently, Dr. Keller is a Professor in the Departments of Urology and Pathology at the University of Michigan.
Nouri Neamati is the John G. Searle Professor of Medicinal Chemistry at the University of Michigan College of Pharmacy. He obtained a Ph.D. in biomedical sciences from the University of Texas Graduate School of Biomedical Sciences and M.D. Anderson Cancer Center, Houston, Texas in 1995. From 1995 to 2000 he was a postdoctoral fellow and a research fellow at the National Institutes of Health. In September 2000, he joined the University of Southern California School of Pharmacy with a joint appointment at the Norris Comprehensive Cancer Center, rising to the rank of professor in 2011. Dr.
Scott A. Tomlins, M.D., Ph.D., obtained his M.D. and Ph.D. at the University of Michigan Medical School (UMMS). His thesis, completed under the mentorship of Arul Chinnaiyan, M.D., Ph.D., described the identification and characterization of recurrent ETS gene fusions in prostate cancer. He completed residency in Anatomic Pathology at the University of Michigan Health System in June 2012 and is an Assistant Professor of Pathology and Urology, and a member of the Michigan Center for Translational Pathology (MCTP) at UMMS. Dr.
Dr. Lombard received a Ph.D. in Biology from Massachusetts Institute of Technology (2000) and an M.D. from Harvard Medical School (2001). He completed residency training in Anatomic Pathology (2001-2003) at Brigham and Women's Hospital in Boston. Following residency training Dr. Lombard joined the laboratory of Professor Frederick Alt at Children's Hospital as a Posdoctoral Fellow. He continued in this role until joining the faculty of the Department of Pathology in September 2008.